Crinetics Q1 2026: PALSONIFY net revenue $10.3M; EU approval; net loss $127.8M

Crinetics Pharmaceuticals, Inc.

2026-Q1 EPS reported -$1.23 revenue$10,734,000

PALSONIFY net product revenue $10.3M in Q1 2026, up from $5.4M in Q4 2025; 232 enrollment forms received.
European Commission approved PALSONIFY for acromegaly in April 2026; MAA submitted to Brazil, NDA in Japan.
Net loss $127.8M vs $96.8M in Q1 2025; cash $1.3B after $380M equity offering.
Initiated BALANCE-CAH Phase 2/3 trial; on track to start Phase 2/3 trial for atumelnant in Cushing's in Q2 2026.
2026 GAAP operating expense guidance $600M-$650M; non-GAAP $480M-$520M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $10.7 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $10.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ACTH antagonist, atumelnant, in a broad population including patients with both Cushing’s disease and ectopic ACTH syndrome. First Quarter 2026 Financial Results: • Revenue was $10.7 million for the quarter ended March 31, 2026, compared to $0.4 million for the same period in 2025. Revenue for the quarter ended March 31, 2026 includes $10.3 million in net product

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001658247-26-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.